TXG 10x Genomics margins

?
Relative Growth: Rel. Growth: 31
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 6
Relative Profitability: Rel. Profitability: 36
Gross margin
71.9%
Operating margin
-11.7%
EBITDA margin
-2.9%
Net margin
-10.8%

10x Genomics shows a gross margin of 71.9%, an operating margin of -11.7%, an EBITDA margin of -2.9%, and a net margin of -10.8%, but its operating margin is negative at -11.7%, its EBITDA margin is negative at -2.9%, and its net margin is negative at -10.8%. All reported margins improved year over year, led by gross margin with an increase of 3.1 percentage points.

TXG margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, 10x Genomics's margins averaged 68.11% gross, -24.13% operating, -14.19% EBITDA, and -21.98% net. All four current margins are above their three-year averages.

TXG margin expansion

Year-over-year margin changes in percentage points

All available margins expanded year over year, led by gross margin with an increase of 3.1 percentage points.

Gross margin expansion
3.1pp
Operating margin expansion
2.5pp
EBITDA margin expansion
1.9pp
Net margin expansion
1.1pp

TXG Gross margin

Across the last 3 years, 10x Genomics's gross margin averaged 68.11%. The current gross margin stands at 71.9%, 3.8 percentage points above its three-year average. Gross margin was highest at 71.9% in Sep 2026 and lowest at 64.6% in Mar 2024.

TXG Operating margin

The average operating margin for 10x Genomics was -24.13% over the last 3 years. 10x Genomics currently reports an operating margin of -11.7%, 12.4 percentage points above its three-year average. The operating margin for 10x Genomics moved between -43.9% in Mar 2024 and -6.1% in Mar 2026.

TXG EBITDA margin

Over the last 3 years, 10x Genomics's EBITDA margin averaged -14.19%. At present, 10x Genomics's current EBITDA margin is -2.9%, which is 11.3 percentage points above its three-year average. During this period, EBITDA margin reached a high of 4.2% in Mar 2026 and a low of -33.6% in Mar 2024.

TXG Net margin

In the last 3 years, 10x Genomics had an average net margin of -21.98%. 10x Genomics currently reports a net margin of -10.8%, 11.2 percentage points above its three-year average. Looking back over the last 3 years, 10x Genomics's net margin reached -3.5% at its highest point in Mar 2026 and -42.3% at its lowest in Mar 2024.

TXG margin group comparison

Margins compared with peer-group, industry and sector averages

With a gross margin of 71.9%, TXG ranks higher than the Healthcare sector and the industry average. But in comparison with the Healthcare sector average of 68.6%, 10x Genomics's gross margin is only 4.8% higher.

TXG margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is 10x Genomics's gross margin?

As of Sep 30, 2026, TXG has a gross margin of 71.9%.

What is 10x Genomics's operating margin?

As of Sep 30, 2026, TXG has a negative operating margin of -11.7%.

What is 10x Genomics's EBITDA margin?

As of Sep 30, 2026, TXG has an EBITDA margin of -2.9%.

What is 10x Genomics's net margin?

For the period ending Sep 30, 2026, TXG recorded a net margin of -10.8%.

What are the average margins of TXG?

10x Genomics's average margins over the last 3 years were 68.1% gross, -24.1% operating, -14.2% EBITDA, and -22.0% net.

What are the highest historical margins of TXG?

In the last 5 years, the highest margins reported by TXG were 84.9% gross in Dec 2021, -6.1% operating in Mar 2026, 4.2% EBITDA in Mar 2026, and -3.5% net in Mar 2026.

What are the lowest historical margins of TXG?

Within the 5-year period, TXG recorded its lowest margins at 64.6% gross in Mar 2024, -43.9% operating in Mar 2024, -33.6% EBITDA in Mar 2024, and -42.3% net in Mar 2024.